Skip to content

Magnetic marker localization for non-palpable breast cancer

Magnetic marker localization for non-palpable breast cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON23325
Enrollment
10
Registered
2019-07-18
Start date
2019-07-29
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

All patients will receive a radioactive iodine seed (Bard Medical, Covington, USA) as per standard care, and the magnetic marker (Magseed, Endomag, Cambridge, UK). A radiologist will first implant the
however, it will only be used as a back-up for when localization through the magnetic probe is not possible or when the surgeon feels unsure about the location determined with the magnetic probe. Once

Sponsors

None
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: I. Female patients aged 18 years or older; II. Patients have biopsy-confirmed, unifocal, non-palpable breast cancer; III. Patients are eligible for breast-conserving surgery; IV. Patients did not undergo any neo-adjuvant treatment; V. Patients are willing and able to provide written informed consent.

Exclusion criteria

Exclusion criteria: I. The patient has a pacemaker.

Design outcomes

Primary

MeasureTime frame
The primary outcome measure is retrieval rate of the magnetic marker using only the magnetic probe.

Secondary

MeasureTime frame
Secondary outcome measures are resection margins, collected from pathology reports and radiologist and surgeon satisfaction, determined through questionnaires.

Contacts

Public ContactIris Noordhoek

Leids Universitair Medisch Centrum

i.noordhoek@lumc.nl+31715264576

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)